Keros Therapeutics (KROS) CFO logs automatic 4,739-share tax sell-to-cover

Rhea-AI Filing Summary

Keros Therapeutics, Inc. chief financial officer Keith Regnante reported an automatic open-market sale of common stock tied to tax withholding on vested restricted stock units. He sold 4,739 shares on February 18, 2026 at a weighted average price of $16.35 per share, in multiple trades between $16.05 and $16.65. After these sell-to-cover transactions, he beneficially owns 39,261 shares of Keros Therapeutics common stock directly.

Insider Trade Summary

Net Seller: 4,739 shares ($77,483)

Net Sell 1 txn

Insider Regnante Keith

Role CHIEF FINANCIAL OFFICER

Sold 4,739 shs ($77K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,739	$16.35	$77K

Holdings After Transaction: Common Stock — 39,261 shares (Direct)

Footnotes (1)

1. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.05 to $16.65 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Regnante Keith

(Last) (First) (Middle)

C/O KEROS THERAPEUTICS, INC.

1050 WALTHAM STREET, SUITE 302

(Street)

LEXINGTON MA 02421

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Keros Therapeutics, Inc. [ KROS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/18/2026		S		4,739(1)	D	$16.35(2)	39,261	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.05 to $16.65 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Keith Regnante	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Keros Therapeutics (KROS) report for Keith Regnante?

Keros Therapeutics reported that CFO Keith Regnante sold 4,739 shares of common stock. The sale was an automatic sell-to-cover transaction related to tax withholding on vested restricted stock units, rather than a discretionary open-market sale for investment purposes.

How many Keros Therapeutics (KROS) shares did the CFO sell and at what prices?

Keith Regnante sold 4,739 Keros Therapeutics common shares at a weighted average price of $16.35. The shares were sold in multiple trades, with individual transaction prices ranging from $16.05 to $16.65 per share, according to the Form 4 disclosure.

Why did the Keros Therapeutics (KROS) CFO sell shares in this Form 4 filing?

The shares were sold under a sell-to-cover policy to satisfy tax withholding obligations. The Form 4 states the sales covered taxes due from the vesting of restricted stock units and were automatic, not made at the CFO’s personal discretion in the open market.

How many Keros Therapeutics (KROS) shares does Keith Regnante hold after this transaction?

After the reported sell-to-cover transaction, Keith Regnante beneficially owns 39,261 shares of Keros Therapeutics common stock directly. This post-transaction holdings figure is disclosed in the Form 4 and reflects his remaining equity position following the 4,739-share sale.

What does weighted average price mean in the Keros Therapeutics (KROS) Form 4?

The weighted average price of $16.35 reflects the blended price of all shares sold across multiple trades. The filing notes that individual sales occurred between $16.05 and $16.65, and detailed price breakdowns are available upon request from the company or the reporting person.